Short‐term intensive insulin therapy could be the preferred option for new onset Type 2 diabetes mellitus patients with HbA1c > 9%: HbA1c>9%的新发2型糖尿病患者可能需要首选胰岛素进行短期强化治疗
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This method is supported by previous research, indicating that early intensified insulin therapy can preserve β-cell function and improve long-term blood glucose control (9, 10, 11).”
From Effectiveness of internet-based management in newly diagnosed young adults with type 2 diabetes: a prospective comparative study (2025) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066 · cited 2×
“Lack of patient education resources in primary care and of provider knowledge as to approaches to insulin treatment (insulin initiation dosage, multiple daily injection or basal insulin supplement, insulin treatment duration) are major obstacles to selecting appropriately intensive but also timely therapy for newly di…”
BackgroundPancreatic β Cell Dedifferentiation as a Mechanism of Diabetic β Cell Failure
Talchai, C., Xuan, S., Lin, H. V., Sussel, L., & Accili, D. (2012) · Cell · doi:10.1016/j.cell.2012.07.029 · Cited by 1,415
Weng, J., Li, Y., Xu, W., Shi, L., Zhang, Q., Zhu, D., Hu, Y., Zhou, Z., Yan, X., Tian, H., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60762-x · Cited by 780
Self-citationGoldstein, B. J., Feinglos, M. N., Lunceford, J. K., Johnson, J., Williams-Herman, D. E., & for the Sitagliptin 036 Study Group (2007) · Diabetes Care · doi:10.2337/dc07-0627 · Cited by 509
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2017) · Endocrine Practice · doi:10.4158/ep161682.cs · Cited by 435
Ilkova, H., Glaser, B., Tunçkale, A., Bagriaçik, N., & Cerasi, E. (1997) · Diabetes Care · doi:10.2337/diacare.20.9.1353 · Cited by 269 · cited 1×
“STII can quickly normalize glycemic control, improve beta-cell function, restore first-phase insulin secretion, and even reduce glucagonemia in newly diagnosed T2DM, suggesting that it might provide unique capacity for modification of the natural process of diabetes (9-15).”
Background
Research works printed but not linked: 25
- 10.2337/dc16-0586 · DOI
- 10.4158/EP.13.3.260 · DOI
- 10.1002/dmrr.2603 · DOI
- 10.2337/dcS15-3003 · DOI
- 10.1002/pds.2262 · DOI
- 10.2337/diacare.27.11.2597 · DOI · Paper page
- 10.2310/6650.2007.06036 · DOI
- 10.3904/kjim.2010.25.3.273 · DOI
- 10.1111/j.1463-1326.2010.01254.x · DOI
- 10.1152/ajpendo.00447.2013 · DOI
- 10.1210/jc.2015-1947 · DOI
- 10.2337/dc08-0075 · DOI · Paper page
- 10.1016/S2213-8587(13)70006-8 · DOI · Paper page
- 10.1016/j.cmet.2014.03.010 · DOI · Paper page
- 10.1016/j.metabol.2011.01.018 · DOI
- 10.1507/endocrj.EJ12-0315 · DOI
- 10.1111/1753-0407.12054 · DOI · Paper page
- 10.1136/bmjdrc-2016-000270 · DOI · Paper page
- 10.1185/03007995.2011.573623 · DOI · Paper page
- 10.1111/j.1365-2753.2010.01552.x · DOI
- 10.4093/dmj.2013.37.6.465 · DOI
- 10.1016/j.clinthera.2012.07.007 · DOI
- 10.1111/joim.12447 · DOI
- 10.1111/j.1463-1326.2009.01129.x · DOI
- 10.1111/j.1463-1326.2012.01658.x · DOI
Cited by
Li, L.-Q., Yao, M.-Y., Ma, J.-X., Xue, P., & Li, Y.-K. (2019) · Endocrine Journal · doi:10.1507/endocrj.ej19-0016 · Cited by 20
“CSII-based short-term intensive treat‐ ment in patients with newly diagnosed type 2 diabetes is very effective in improving glycemic and lipid control, β-cell function, and insulin sensitivity, and it is thought to be suitable for newly diagnosed type 2 diabetes, espe‐ cially for patients with HbA1c > 9% [16].”
BackgroundLi, Z., Luo, D., & Li, Z. (2025) · Endocrine Connections · doi:10.1530/ec-24-0576 · Cited by 6
Metadata
- Authors
- Weng, J.
- Affiliations
- Department of Endocrinology and Metabolism The Third Affiliated Hospital of Sun Yat‐sen University, Guangdong Provincial Key Laboratory of Diabetology Guangzhou China
- Venue
- Journal of Diabetes
- Publisher
- Wiley
- Published
- 2017-08-22
- Volume
- 9
- Issue
- 10
- Pages
- 890-893
- ISSN
- 1753-0393
- 1753-0407
- Cited by
- 19
- References
- 6
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.